Submitted by Anonymous (not verified) on 22 September 2026 - 14:08
Human medicines European public assessment report (EPAR): Tacquell, Autologous melanoma-derived tumor infiltrating lymphocytes, ex vivo-expanded, Date of refusal: 14/09/2026, Status: Refused
Source: